

## Expressional and Epigenetic Alterations of Placental Serine Protease Inhibitors

### *SERPINA3* Is a Potential Marker of Preeclampsia

Sonia T. Chelbi, Françoise Mondon, Hélène Jammes, Christophe Buffat, Thérèse-Marie Mignot, Jorg Tost, Florence Busato, Ivo Gut, Régis Rebourcet, Paul Laissue, Vassili Tsatsaris, François Goffinet, Virginie Rigourd, Bruno Carbonne, Françoise Ferré, Daniel Vaiman

**Abstract**—Preeclampsia is the major pregnancy-induced hypertensive disorder. It modifies the expression profile of placental genes, including several serine protease inhibitors (*SERPINS*). The objective of this study was to perform a systematic expression analysis of these genes in normal and pathological placentas and to pinpoint epigenetic alterations inside their promoter regions. Expression of 18 placental *SERPINS* was analyzed by quantitative RT-PCR on placentas from pregnancies complicated by preeclampsia, intrauterine growth restriction, or both and was compared with normal controls. *SERPINA3*, *A5*, *A8*, *B2*, *B5*, and *B7* presented significant differences in expression in  $\geq 1$  pathological situation. In parallel, the methylation status of the CpG islands located in their promoter regions was studied on a sample of control and preeclamptic placentas. Ten *SERPIN* promoters were either totally methylated or totally unmethylated, whereas *SERPINA3*, *A5*, and *A8* presented complex methylation profiles. For *SERPINA3*, the analysis was extended to 81 samples and performed by pyrosequencing. For the *SERPINA3* CpG island, the average methylation level was significantly diminished in preeclampsia and growth restriction. The hypomethylated CpGs were situated at putative binding sites for developmental and stress response (hypoxia and inflammation) factors. Our results provide one of the first observations of a specific epigenetic alteration in human placental diseases and provide new potential markers for an early diagnosis. (*Hypertension*. 2007;49:76-83.)

**Key Words:** preeclampsia ■ intrauterine growth restriction ■ placenta ■ serine protease inhibitors ■ epigenetics

Hypertension during pregnancy includes preeclampsia (PE), gestational hypertension, and pre-existing chronic essential hypertension. From a clinical point of view, PE associates with hypertension, proteinuria, and, in the majority of cases, mild-to-severe edema. It is the most prevalent obstetric complication ( $\leq 10\%$  of the pregnancies<sup>1</sup>) and may lead to maternal and fetal morbidity and mortality.<sup>2</sup> The physiopathological process includes endothelial dysfunctions,<sup>3</sup> oxidative stress,<sup>4,5</sup> exaggerated inflammatory responses,<sup>6</sup> thrombosis, and renin-angiotensin-aldosterone system activation.<sup>7</sup> This multisystemic disease can lead to severe clinical conditions, such as eclampsia, when generalized seizures appear, and hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome when a hemolytic process is observed. In  $>25\%$  of the cases, the reduced vascular flow at the fetoma-

ternal interface induces an intrauterine growth restriction (IUGR). Early caesarean delivery of the fetus is the classical treatment for PE, leading to iatrogenic low-weight newborns. Thus, PE contributes to the risk of developing a metabolic syndrome later in life.<sup>8</sup>

Although preeclamptic women typically develop clinical signs and symptoms from midgestation, it is now widely admitted that the physiopathological process starts as early as the end of the first trimester of pregnancy.<sup>9</sup> In PE, cytotrophoblasts fail to invade deeply spiralled uterine arteries.<sup>9-11</sup> This shallow invasion leads to localized ischemic lesions and hypoxia.<sup>12,13</sup> Consequently, placental endothelial residues<sup>14,15</sup> originating from the fetoplacental unit are released into the maternal blood flow, probably inducing the hypertensive state.<sup>16</sup>

Received August 21, 2006; first decision September 11, 2006; revision accepted October 13, 2006.

From the Equipe 21 (S.T.C., F.M., H.J., T.-M.M., R.R., P.L., B.C., V.R., B.C., F.F., D.V.), Génomique et Epigénétique des Pathologies Placentaires, Unité INSERM 567/UMR Centre National de la Recherche Scientifique 8104, Université Paris V IFR Alfred Jost, Faculté de Médecine, Cochin-Port-Royal, Paris, France; PHASE Department (H.J.), Institut National de la Recherche Agronomique, Jouy-en-Josas, France; Faculté de Médecine (C.B.), Université de la Méditerranée et Service de Néonatalogie, Hôpital de la Conception AP-HM, Marseille, France; Laboratoire d'épigénétique (J.T., F.B., I.G.), Centre National de Génotypage, Evry, France; Service de Gynécologie-Obstétrique (V.T., F.G.), Université Paris V, Faculté de Médecine, APHP, Hôpital Cochin, Paris, France; Service de Gynécologie-Obstétrique (B.C.), Hôpital Saint Antoine, Paris, France; and the Animal Genetics Department (D.V.), Institut National de la Recherche Agronomique Jouy-en-Josas, France.

Correspondence to Daniel Vaiman, Equipe 21, Génomique et Epigénétique des Pathologies Placentaires, Unité INSERM 567/UMR CNRS 8104, Université Paris V IFR Alfred Jost, Faculté de Médecine, Cochin-Port-Royal, 24 Rue du Faubourg Saint-Jacques, 75014 Paris, France. E-mail vaiman@cochin.inserm.fr

© 2006 American Heart Association, Inc.

*Hypertension* is available at <http://www.hypertensionaha.org>

DOI: 10.1161/01.HYP.0000250831.52876.cb

The etiology of PE remains poorly understood. Medically assisted procreation increases the risk of PE,<sup>17</sup> suggesting that early gamete alterations (of epigenetic origin) may be sufficient to induce placental defects. Genetic factors are also involved in the pathogenesis of PE, because several genomic regions have been linked to the disease.<sup>18–23</sup> Recently, *STOX1* missense mutations have been shown to predispose to PE.<sup>24</sup> Today, no univocal predicting indicator has been described for PE, although endoglin, an endothelial cell homodimeric transmembrane glycoprotein, has been proposed recently as a promising early marker.<sup>25</sup>

We have attempted recently to approach the major placental diseases by transcriptome analysis.<sup>26,27</sup> We confirmed that *SERPING1*, *SERPINE1*, and *SERPINE2*, members of the serine protease inhibitor (*SERPIN*) gene family, are induced by hypoxia and often modified in terms of expression in placentas from preeclamptic pregnancies. Other studies have shown plasma level modifications of *SERPINA8*, *E1*, and *B2* in preeclamptic women.<sup>28–31</sup> *SERPIN* genes encode  $\geq 36$  proteins with a complex conserved structure but various functions.<sup>32</sup> They act as protease inhibitors and are characterized by their “suicide” behavior, involving an unusual covalent binding with the target protease(s), before degradation of the *SERPIN*–protease complex.<sup>33</sup> They also serve as storage proteins (ovalbumin), carrier proteins (steroid-binding globulin), and hormone precursors (angiotensinogen or *SERPINA8*) without inhibitory function. They are homeostasis guardians that regulate several molecular pathways, such as inflammation, coagulation, fibrinolysis, complement activation, and phagocytosis. All of these cascades are affected in placental diseases.<sup>32,34</sup> Recent data begin to accumulate about the involvement of epigenetic promoter marks (mostly DNA methylation) in genes important for placental physiology. For instance, syncytin, a glycoprotein encoded by a human endoretrovirus, of crucial importance for syncytiotrophoblast formation displays a tissue specificity associated with promoter demethylation.<sup>35</sup>

Our working hypothesis is that a systematic analysis of *SERPIN* expression conjointly with the study of epigenetic promoter alterations will permit us to sort out specific early markers of placental diseases. Thus, the expression of 18 *SERPIN* was analyzed in normal and pathological placentas. In addition, we attempted to correlate their mRNA levels with DNA methylation alterations of their promoter regions.

## Methods

### Human Material Samples and Ethics

Placentas from normal and pathological pregnancies (PE and IUGR) were collected after cesarean delivery from 3 maternities (St Antoine, Port-Royal, and Institut de Puériculture, Paris, France) following the indications of the Hôpital Cochin ethical committee. We had access to complete clinical data for each individual (summarized in the Table). The inclusion criteria used for PE patients were the following clinical thresholds: systolic pressure  $>140$  mm Hg, diastolic pressure  $>90$  mm Hg, and proteinuria  $>0.3$  g per 24 hours. The inclusion criteria used for IUGR was weight at birth  $<10$ th percentile. We classified the patients in 3 groups: isolated PE (PE), PE associated with IUGR (PE+IUGR), and isolated IUGR (IUGR). The control group was formed by women who underwent caesarean surgery without suffering any disease during pregnancy.

Fragments (10 to 20 mm) from the placental subchorial zone were dissected as described previously.<sup>26,27</sup> Maternal membranes were eliminated, and floating villi were washed in Hanks' balanced salt solution. A fraction of these samples was kept in TRIzol (5 mL/g, Invitrogen), and total RNA was extracted, treated with RNase-free DNase, and quantified by spectrophotometry. Genomic DNA was extracted from chorionic villi after mechanical grinding using an electric Ultraturax homogenizer in lysis solution (NaCl 50 mmol/L, Tris-HCl 10 mmol/L [pH 7.4], EDTA 10 mmol/L, and 0.2% SDS) and treated with Proteinase K (1 g/L final concentration) for 3 to 12 hours at 55°C. The DNA was precipitated, washed with 70% ethanol, and quantified.

### Primers and Quantitative RT-PCR Conditions

Reverse transcription was carried out according to a standardized protocol.<sup>26</sup> Briefly, 2  $\mu$ g of total DNase-treated RNA was reverse transcribed in a volume of 25  $\mu$ L at 39°C using the Superscript reverse transcriptase (Invitrogen) during 1 hour. Quantitative RT-PCR was carried out in duplicates on 8 control, 9 PE, 7 PE+IUGR, and 8 IUGR placentas. The amplification kit Platinum SYBR Green Mastermix (Invitrogen) was complemented with  $MgCl_2$  (4 mmol/L final concentration), BSA (0.05 g/L), and primers ( $10^{-3}$  mmol/L) to a final volume of 17  $\mu$ L. The reaction was performed in a Light Cycler Thermocycler (Roche). Primers (Table IA supplementary data, please see <http://hyper.ahajournals.org>) were designed for the coding sequences (GENBANK) of the different *SERPINS* using the PRIMER3 software (<http://frodo.wi.mit.edu/cgi-bin/primer3>). The different couples were chosen to recover all of the previously described isoforms and aligned with basic local alignment search tool software to avoid nonspecific annealing. We used the PCR program: 50°C for 120 s and 95°C for 120 s followed by 35 cycles of 3 temperature steps (94°C for 5 s, 58°C for 10 s, and 72°C for 30 s). Finally, samples were submitted to a progressive temperature elevation (from 65 to 99°C at 0.1°C/s), resulting in a fusion curve, enabling us to check the PCR products homogeneity. In addition, amplification products were systematically controlled by agarose gel electrophoresis. The threshold cycle number (Ct) values were collected with the LightCycler software (Roche) in the exponential phase of the PCR reaction. These Cts were normalized by the Ct values obtained for the succinate dehydrogenase subunit A (*SDHA*) used as a reporter gene and shown previously to be stable and highly expressed in the placenta.<sup>36</sup>

### Methylation Analysis of CpG Islands Inside the Promoter Regions by Sequencing

DNA was denatured during 5 minutes at 100°C and incubated 20 minutes at 37°C in a 0.2-mol/L NaOH solution. Deamination was carried out in the dark with sodium bisulphite (4.6 mol/L final concentration) and hydroxyquinone (120 mmol/L final concentration) for 4 hours at 55°C. The DNA was then purified with the Wizard DNA clean-up kit (Promega) and rinsed 3 times with isopropanol. The bisulphite conversion was completed by incubation with 0.3 mol/L of NaOH during 20 minutes at 37°C. The DNA was then precipitated (0.5 volumes of 6 mol/L of ammonium acetate, 1  $\mu$ L of glycogen (Invitrogen), and 2.5 volumes of absolute ethanol), washed with 70% ethanol, dried, and resuspended in distilled water.

For each *SERPIN* gene, CpG islands were screened on the 10 kb upstream of the transcription start site and defined by a CpG dinucleotides density  $>50$  in 1000 bp (Figure I, available online at <http://hyper.ahajournals.org>). When no CpG island was detectable under these conditions, we searched for local CpG density and putative binding site(s) for the hypoxia-inducible factor  $\alpha$  subunit (HIF-1 $\alpha$ ). We used a nested PCR approach; therefore, we designed 2 couples of primers for each *SERPIN* to obtain a final product of  $\approx 500$  bp. For primer design, the criteria were as follows: (1) annealing with bisulphite-treated DNA without covering any CpG, (2) a similar temperature ( $\approx 56^\circ\text{C}$ ), and (3) a primer length close to 20 bp. PCR primer couples for *SERPINA3* are 5'-AAGAGGTAG-AGGATAGGG-3', 5'-ATACTATAAACACTCTCTCT-3' for the primary PCR reaction, and 5'-GGAGAATTTGATTAGGAGAA-3',

**Clinical Characteristics of Patients Analyzed at the Transcriptional Level**

Placenta No.	Status	Weeks Amenorrhea	Mother Age	HTA	Proteinuria (g/24 h)	Uterine Doppler (N=notch)	Oligoaminos	Birth Weight (g)	Percentile
766	PE	37+4	45	140/90	1.70	N=1/1	nd	2930	>10th
867	PE	33+1	26	170/90	5.36	nd	0	1930	>10th
885	PE	30+0	22	175/105	8.68	0/0	0	1080	>10th
898	PE	29+2	33	165/100	4.00	0/0	0	1960	>10th
972	PE	34+5	40	150/80	0.87	N=0/1	0	1196	>10th
866	PE	29+3	24	140/90	2.70	nd	0	1390	>10th
868	PE+edemas	32+5	36	160/110	14.36	nd	0	995	>10th
869	PE+HELLP	34+2	36	160/80	3.00	N=2/2	0	1180	>10th
971	PE+retroplacental hematoma	30+1	29	160/80	2.50	nd	0	1620	>10th
846	PE+IUGR	28+5	32	205/120	10.69	0/0	0	830	5th<<10th
853	PE+IUGR	34+1	37	140/90	6.98	0/0	0	1800	5th<<10th
772	PE+IUGR+HELLP	28+0	37	160/100	3.00	N=2/2	1	780	5th
775	PE+IUGR	33+6	37	140/90	1.27	nd	1	1550	<5th
871	PE+IUGR	34+1	36	180/120	2.10	0/0	1+	1670	<5th
887	PE+IUGR	38+0	43	150/90	46.00	0/0	0	1180	<5th
872	PE+IUGR	32+6	33	140/90	1.04	N=0/2	0	2400	5th<<10th
773	IUGR	37+3	26	160/90	0.00	N=2/2	nd	1890	5th<<10th
810	IUGR	31+3	35	Normal	0.00	N=0/2	1	1380	5th<<10th
811	IUGR	37+0	33	Normal	0.00	nd	1	2330	5th<<10th
814	IUGR	29+2	25	Normal	0.00	N=2/2	1	670	<5th
841	IUGR	32+3	20	Normal	0.00	0/0	0	1340	5th<<10th
873	IUGR	38+0	39	Normal	0.00	N=2/0	1	2550	5th<<10th
910	IUGR	31+6	29	Normal	0.00	0/0	0	1260	5th<<10th
911	IUGR	35+1	30	Normal	0.00	N=1/2	1	1590	<5th
791	Term (control)	38+5	43	Normal	0.00	0/0	nd	3430	>10th
820	Term (control)	37+5	41	Normal	0.00	0/0	nd	2740	>10th
774	Term (control)	38+5	41	Normal	0.00	0/0	nd	3110	>10th
823	Term (control)	38+0	35	Normal	0.00	0/0	0	3500	>10th
826	Term (control)	37+0	32	Normal	0.00	0/0	0	3380	>10th
829	Term (control)	38+0	37	Normal	0.00	0/0	nd	3710	>10th
830	Term (control)	39+0	28	Normal	0.00	0/0	nd	2900	>10th

The Notch (N) is represented by 2 values; the first corresponds with a measure at the second trimester and the second value at the third trimester. 1 indicates unilateral notch; 2, bilateral notch; nd, not determined.

5'-CCCCCTAATTCCATTCTTC-3' for the secondary PCR reaction. The complete list of postbisulphite primers is given as supplementary data (Table IB). The products were either gel purified using QIAquick columns (QIAGEN) for direct sequencing or ligated into pCR4 Topo vector (Invitrogen), cloned into electrocompetent Top10 bacteria (Invitrogen), and sequenced. In either case, analyses were carried out on 5 control and 5 PE placentas. Sequences were analyzed using the BioEdit software (sequence alignment editor) on the raw and interpreted data as well.

### Methylation Analysis of CpG Islands Inside the Promoters Regions by Pyrosequencing

For *SERPINA3*, amplicons encompassing the selected CpG island were designed with 1 of the 2 primers being biotinylated. Forty-seven placental DNAs from PE, 16 from IUGR, and 18 from control subjects were treated with sodium bisulphite and amplified by PCR. The template for pyrosequencing was purified, rendered single stranded, and analyzed by serial pyrosequencing to evaluate the methylation percentage at each CpG position.<sup>37,38</sup>

### Promoter Composition Analysis

The putative transcription factor binding sites inside the *SERPINA3* promoter sequence were obtained using the Genomatix software (<http://genomatix.de>).<sup>39</sup>


### Statistical Analysis

The averaged normalized Ct values of each pathological group were compared with the averaged Ct value obtained for the control group, using Student's *t* test. Details about multivariate principal component analysis are given as supplementary data (available at <http://hyper.ahajournals.org>), together with their statistical validation methods.

## Results

### Analysis of SERPIN Expression in Normal and Pathological Placentas

Quantitative RT-PCR was carried out for 18 *SERPINS* on a panel of nonpathological and pathological near-term placentas. The expression levels varied on 4 orders of magnitude



**Figure 1.** Quantitative RT-PCR results. The  $\Delta C_t$  was normalized with *SDHA*. The data are represented as ratios of induction/diminution for each *SERPIN* using the average value in each pathological case. Significantly modified *SERPINS* are labeled with asterisks (\* $<5\%$  and \*\* $<1\%$ ), and their names are represented in  $\square$ .

between the different *SERPINS*. on average, the *SERPIN A* clade (composed of *SERPINA1*, *A3*, *A5*, and *A8* in our panel) is significantly underexpressed compared with the *SERPIN B* clade (or ovalbumins, *SERPINB1*, *B2*, *B5*, *B6*, *B7*, *B8*, and *B9*) by a factor of 30 on average ( $P=0.036$ ). We did not find evidence of a relationship between expression level and chromosome location. Indeed, although several *SERPINS* map in clusters (Figure IB), wide differences in expression can be observed between consecutive genes.


The expression level was analyzed in the 3 pathological states. The ratio of the average expression levels between each pathological situation (PE, PE+IUGR, and IUGR) and the control are shown in Figure 1. Although several *SERPINS* vary similarly in the 3 pathological conditions (*SERPINA3*, *A5*, *B2*, and *B7*), 3 distinct *SERPIN* expression profiles distinguish the 3 pathological states.

For a refined description of the data we performed a multivariate analysis by principal component analysis (Figure II). This analysis indicates that, on the whole, 6 *SERPIN* do not vary much with the pathological state (*SERPINH1*, *B9*, *B6*, *E1*, *G1*, and *F1*). Conversely, *SERPINA8*, *B5*, *A3*, *A5*, and *B2* are the most widely modified. This analysis also permitted us to classify efficiently the disease states according to the pathological condition. On the graph (Figure II), isolated preeclamptic samples were clearly separated from isolated

IUGR samples. Furthermore, PE+IUGR were the clinical situations where expression alterations were the highest. Interestingly, part of these samples (placentas 846, 853, 871, and 872) were closer to the PE-only situation, whereas others (placentas 772, 775, and 887) were closer to the IUGR-only situation.

**Epigenetic Regulation/Dysregulation of *SERPIN* in Normal and Pathological Placentas**

We attempted to correlate levels of expression with promoter methylation, because in the classical view, a high methylation level is associated with gene silencing. One or 2 CpG islands were chosen for each *SERPIN* (Figure I and Table IB in the supplementary data). The direct sequencing of the amplicons showed that the CpG islands of *SERPINB1*, *B9*, and *B8* were totally unmethylated, whereas those of *SERPINA1*, *B7*, *D1*, *F1*, and *H1* were totally methylated. For *SERPING1* and *I1*, 2 CpG islands were studied, showing discrepant results (the CpG island located closest to the transcription start site is unmethylated in both cases, whereas the one located farther was totally methylated). On average, the unmethylated promoter was associated with an increased (8 times) expression level. For *SERPINA5*, *A8*, *A3*, and *E1*, the direct sequencing approach did not clearly identify a methylation profile. Thus, we used a cloning/sequencing protocol after bisulphite treat-



**Figure 2.** Methylation averages of 14 CpGs inside the promoter of *SERPINA3*, in all of the PE, isolated IUGR, and control subjects. The whole sequence is significantly hypomethylated in preeclampsia. This is particularly marked on specific positions where the variation is significant: 1, 2, 4, 6, and 12. Strong variations are visible between consecutive CpG (from  $\approx 17\%$  for CpG3 to  $\approx 70\%$  for CpG5). Significantly demethylated positions in PE compared with control are marked by asterisks (\* $<5\%$ , \*\* $<1\%$ , and \*\*\* $<0.1\%$ ).

ment for analyzing the *SERPINA5*, *A8*, and *A3* CpG islands. Five control and 5 PE placentas were analyzed, and 10 to 14 clones were sequenced for each of them. For *SERPINA5* and *A8*, the cloning/sequencing procedure revealed a marked heterogeneity between consecutive CpGs and among individuals. Nevertheless, no correlation with the disease status was observed (data not shown). By contrast, the CpG island of *SERPINA3* seemed significantly undermethylated in PE (paired *t* test;  $P=0.03$ ). To validate this observation, we decided to use the more precise pyrosequencing technique on a larger group of individuals (47 PE, 16 IUGR, and 18 control placental DNAs). As shown in Figure 2, we confirmed the observation of a hypomethylation of this region in pathological placentas using a paired *t* test comparing all of the CpG between the controls and the pathologic samples (PE versus control,  $P=0.00019$  and IUGR versus control,  $P=0.029$ ). The analysis was also carried out by a standard *t* test to evaluate whether given CpG dinucleotides were specifically affected by the pathology-associated hypomethylation. We demonstrated a significant hypomethylation in PE, especially at positions 98, 129, 149, 167, and 497 ( $P=0.00006$ , 0.0004, 0.017, 0.008, and 0.01, respectively). Interestingly, the positions located at the start of the analyzed sequence encompass 2 putative, consecutive *HIF-1 $\alpha$*  binding sites (positions 128 and 137). The first significant CpG positions encompass putative binding sites for homeodomain-containing transcription factors (BRNF, HOXC13, HOXF, and OCTB). The CpG dinucleotide in position 98 is included in a myc-associated Zn finger protein binding site. Finally, the CG dinucleotide in position 497 lies in the only retinoic acid receptor (RXR) binding site of the promoter.

## Discussion

Early diagnosis of placental diseases, such as PE, is a major challenge for being able to dispense the existing treatments (aspirin and low molecular weight heparin).<sup>40,41</sup> Recent ad-

vances suggest that methylation alterations of trophoblastic circulating DNA in the maternal blood is a promising marker for such early detection.<sup>42</sup> However, the choice of the right promoter DNA to be analyzed is crucial. This choice can be guided by strong expression modifications of placental genes. In this study, we focused our interest on placental SERPINS, several of which, indeed, display such alterations. These are probably related to the physiopathogenesis of placental diseases, such as an exaggerated inflammatory response and thrombosis.<sup>6,7</sup> In PE and PE+IUGR, proinflammatory cytokines and substances provoking inflammatory damages, such as specific proteases, are increased.<sup>43</sup> We found an increase of *SERPINA3* expression consistent with its inhibitory role on chymotrypsin to counterbalance inflammation.<sup>44,45</sup> On the other hand, recent studies about this SERPIN indicate that it is a specific inhibitor of elastase.<sup>46,47</sup> Elastase belongs to the matrix metalloprotease family, which plays a crucial role during the implantation process.<sup>48</sup> This may suggest that an increased *SERPINA3* synthesis may inhibit the matrix disintegration necessary for an efficient implantation. Such an effect would be very consistent with the admitted pathogenesis of PE and could imply a very early impact of *SERPINA3* in the onset of placental diseases. If so, the epigenetic modifications observed for this specific gene correspond with a disease-predisposing state rather than a secondary consequence. The *SERPINA5* (protein C inhibitor) is secreted to inactivate several proteases of the fibrinolytic system. Therefore, the reduction observed for *SERPINA5* may serve to control thrombosis. Similarly, *SERPINB2* that participates in fibrinolysis regulation is reduced in placental diseases.<sup>49</sup> Our results are consistent with previous studies, because it has been shown that *SERPINB2* decreases in both PE and IUGR in the maternal serum<sup>50</sup> and that this decrease also correlates with a diminished level of *SERPINB2* mRNA in IUGR placentas.<sup>51</sup> For *SERPINE1* and *SERPINA8*, different studies have shown a PE-induced increase in maternal serum.<sup>50,52</sup> In

our observations, the increase was not significant at the placental level probably because of interindividual heterogeneity, a very common feature of human placentas.<sup>53</sup> Moreover, the placental level of *SERPINE1* mRNA may not be sufficient to reveal alterations observed in the maternal serum, because *SERPINE1* is secreted from other sources than placental villi.<sup>54</sup> For instance, *SERPINE1* is highly expressed in decidual cells, contrary to *SERPINB2*.<sup>54</sup> *SERPINA8* (*AGT*) encodes angiotensinogen and is involved in hypertensive diseases. The T235M substitution<sup>55</sup> is a risk factor for PE, because it occurs at higher frequency in white and Japanese preeclamptic women<sup>56–58</sup> and is linked to higher basal levels of *AGT*. Thus, the high interpatient variations that we observed might be correlated to genetic heterogeneity.

PE and IUGR are sustained pathological conditions (the duration of pregnancy) especially dependent on cell proliferation, differentiation, and invasiveness. The invasive and erosive role of the syncytiotrophoblast is extremely important for the implantation of the young blastocyst at  $\approx 1$  week postfertilization. Despite the tight control governing these processes, they seem similar to the development of malignant tissues.<sup>59,60</sup> In cancer, epigenetic modifications (abnormal DNA methylation and abnormal chromatin structure) are common. DNA methylation can be laid on DNA during cell divisions. In PE, an active cytotrophoblastic division phase is concomitant with the onset of the disease. Therefore, epigenetic alterations in such a rapidly expanding tissue may be expected. Thus, we explored the possibility of PE- and IUGR-induced epigenetic modifications on *SERPIN* promoters. We brought to light significant position-specific CpG demethylations in the *SERPINA3* promoter in pathological states. This hypomethylated pattern might contribute to render the chromatin accessible to transcription factors. Several studies reported that the absence of CpG methylation at HIF-1 $\alpha$  binding sites is required to allow gene transcriptional induction.<sup>61,62</sup> Thus, demethylation may facilitate interaction of this transcription factor with the *SERPINA3* promoter in the hypoxic environment generated in PE. In addition, demethylated CpG in this promoter region is prominently recognized by developmental regulators, such as homeodomain-containing proteins and inflammatory modulators (Myc-associated Zn finger protein and RXR). RXR $\alpha$ /PPAR $\gamma$  heterodimers have been shown to have crucial roles in trophoblast invasion and placental nutrient transport.<sup>63,64</sup> The presence of such binding sites in the *SERPINA3* promoter suggests, therefore, an early function of this gene in placental development. In our experiments, the *SERPINA3* mRNA was increased at a higher level in IUGR or PE+IUGR than in isolated PE. This observation is consistent with a multistep scenario of transcriptional activation: first, in PE but also in isolated IUGR, a promoter demethylation occurs. Then, in IUGR either isolated or combined with PE, the transcription factor environment enables a higher activation of the *SERPINA3* promoter than in isolated PE.

### Perspectives

The observed methylation alterations are quantitative and could, therefore, reflect heterogeneities between the cell types of the placental villi. We intend to address this point by

purifying specific cell types (eg, cytotrophoblasts and perivascular smooth muscle cells) from normal and pathological placentas and studying their methylation level. In addition, the links between methylation alterations and protein expression will be tested by immunohistochemistry using an available antibody. Finally, some recent advances suggest that fetoplacental methylation alterations could be detected in the maternal blood.<sup>65</sup> Therefore, we also intend to evaluate these modifications as markers able to contribute to an early diagnosis. On the other hand, several reports indicate that *SERPINA3* is present in the chromaffin neurosecretory vesicles.<sup>66,67</sup> Therefore, this protein may also be secreted in the maternal blood, and its level could be altered in PE. This issue could be tested in the future on collections of sera of pregnant women.

### Sources of Funding

This work was funded by INSERM. S.T.C. is a recipient of a fellowship from the French Research Ministry (Paris XI University).

### Disclosures

None.

### References

- Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, Goldenberg RL, Joffe G. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. *Am J Obstet Gynecol*. 1997;177:1003–1010.
- Report of the National High Blood Pressure Education Program Working Group on high blood pressure in pregnancy. *Am J Obstet Gynecol*. 2000;183:S1–S22.
- Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. *Lancet*. 2003;361:1511–1517.
- Gupta S, Agarwal A, Sharma RK. The role of placental oxidative stress and lipid peroxidation in preeclampsia. *Obstet Gynecol Surv*. 2005;60:807–816.
- Redman CW, Sargent IL. Latest advances in understanding preeclampsia. *Science*. 2005;308:1592–1594.
- Kharfi A, Giguere Y, Sapin V, Masse J, Dastugue B, Forest JC. Trophoblastic remodeling in normal and preeclamptic pregnancies: implication of cytokines. *Clin Biochem*. 2003;36:323–331.
- Elsheikh A, Creasas G, Mastorakos G, Milingos S, Loutradis D, Michalas S. The renin-aldosterone system during normal and hypertensive pregnancy. *Arch Gynecol Obstet*. 2001;264:182–185.
- Barker DJ. Outcome of low birthweight. *Horm Res*. 1994;42:223–230.
- Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. *Biol Reprod*. 2003;69:1–7.
- Gerretsen G, Huisjes HJ, Elema JD. Morphological changes of the spiral arteries in the placental bed in relation to pre-eclampsia and fetal growth retardation. *Br J Obstet Gynaecol*. 1981;88:876–881.
- Zhou Y, Bellingard V, Feng KT, McMaster M, Fisher SJ. Human cytotrophoblasts promote endothelial survival and vascular remodeling through secretion of Ang2, PlGF, and VEGF-C. *Dev Biol*. 2003;263:114–125.
- Jauniaux E, Gulbis B, Burton GJ. Physiological implications of the materno-fetal oxygen gradient in human early pregnancy. *Reprod Biomed Online*. 2003;7:250–253.
- Kingdom JC, Kaufmann P. Oxygen and placental vascular development. *Adv Exp Med Biol*. 1999;474:259–275.
- Johansen M, Redman CW, Wilkins T, Sargent IL. Trophoblast deportation in human pregnancy—its relevance for pre-eclampsia. *Placenta*. 1999;20:531–539.
- Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response—a review. *Placenta*. 2003;24(suppl A):S21–S27.
- Roberts L, LaMarca BB, Fournier L, Bain J, Cockrell K, Granger JP. Enhanced endothelin synthesis by endothelial cells exposed to sera from

- pregnant rats with decreased uterine perfusion. *Hypertension*. 2006;47:615–618.
17. Wang JX, Knottnerus AM, Schuit G, Norman RJ, Chan A, Dekker GA. Surgically obtained sperm, and risk of gestational hypertension and preeclampsia. *Lancet*. 2002;359:673–674.
  18. Fitzpatrick E, Goring HH, Liu H, Borg A, Forrest S, Cooper DW, Brennecke SP, Moses EK. Fine mapping and SNP analysis of positional candidates at the preeclampsia susceptibility locus (PREG1) on chromosome 2. *Hum Biol*. 2004;76:849–862.
  19. Laasanen J, Hiltunen M, Romppanen EL, Punnonen K, Mannermaa A, Heinonen S. Microsatellite marker association at chromosome region 2p13 in Finnish patients with preeclampsia and obstetric cholestasis suggests a common risk locus. *Eur J Hum Genet*. 2003;11:232–236.
  20. Lachmeijer AM, Arngrimsson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardottir S, Stefansson H, Palsson B, Nicolae D, Kong A, Aarnoudse JG, Gulcher JR, Dekker GA, ten Kate LP, Stefansson K. A genome-wide scan for preeclampsia in the Netherlands. *Eur J Hum Genet*. 2001;9:758–764.
  21. Moses EK, Lade JA, Guo G, Wilton AN, Grehan M, Freed K, Borg A, Terwilliger JD, North R, Cooper DW, Brennecke SP. A genome scan in families from Australia and New Zealand confirms the presence of a maternal susceptibility locus for pre-eclampsia, on chromosome 2. *Am J Hum Genet*. 2000;67:1581–1585.
  22. Arngrimsson R, Sigurdar ttr S, Frigge ML, Bjarnad ttr RI, Jonsson T, Stefansson H, Baldursdottir A, Einarsdottir AS, Palsson B, Snorradottir S, Lachmeijer AM, Nicolae D, Kong A, Bragason BT, Gulcher JR, Geirsson RT, Stefansson K. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. *Hum Mol Genet*. 1999;8:1799–1805.
  23. Lachmeijer AM, Dekker GA, Pals G, Aarnoudse JG, ten Kate LP, Arngrimsson R. Searching for preeclampsia genes: the current position. *Eur J Obstet Gynecol Reprod Biol*. 2002;105:94–113.
  24. van Dijk M, Mulders J, Poutsma A, Konst AA, Lachmeijer AM, Dekker GA, Blankenstein MA, Oudejans CB. Maternal segregation of the Dutch preeclampsia locus at 10q22 with a new member of the winged helix gene family. *Nat Genet*. 2005;37:514–519.
  25. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdoah Y, Lim KH, Yuan HT, Libermann TA, Stillman IE, Roberts D, D'Amore PA, Epstein FH, Sellke FW, Romero R, Sukhatme VP, Letarte M, Karumanchi SA. Soluble endoglin contributes to the pathogenesis of preeclampsia. *Nat Med*. 2006;12:642–649.
  26. Mondon F, Mignot TM, Rebourcet R, Jammes H, Danan JL, Ferre F, Vaiman D. Profiling of oxygen-modulated gene expression in early human placenta by systematic sequencing of suppressive subtractive hybridization products. *Physiol Genomics*. 2005;22:99–107.
  27. Vaiman D, Mondon F, Garces-Duran A, Mignot TM, Robert B, Rebourcet R, Jammes H, Chelbi ST, Quetin F, Marceau G, Sapin V, Piumi F, Danan JL, Rigourd V, Carbonne B, Ferre F. Hypoxia-activated genes from early placenta are elevated in preeclampsia, but not in Intra-Uterine Growth Retardation. *BMC Genomics*. 2005;6:111.
  28. Morgan T, Craven C, Nelson L, Lalouel JM, Ward K. Angiotensinogen T235 expression is elevated in decidual spiral arteries. *J Clin Invest*. 1997;100:1406–1415.
  29. Estelles A, Gilabert J, Grancha S, Yamamoto K, Thinnis T, Espana F, Aznar J, Loskutoff DJ. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. *Thromb Haemost*. 1998;79:500–508.
  30. Ohkuchi A, Minakami H, Aoya T, Haga T, Kimura H, Suzuki M, Sato I. Expansion of the fraction of Th1 cells in women with preeclampsia: inverse correlation between the percentage of Th1 cells and the plasma level of PAI-2. *Am J Reprod Immunol*. 2001;46:252–259.
  31. Page NM, Kemp CF, Butlin DJ, Lowry PJ. Placental peptides as markers of gestational disease. *Reproduction*. 2002;123:487–495.
  32. Silverman GA, Bird PI, Carrell RW, Church FC, Coughlin PB, Gettins PG, Irving JA, Lomas DA, Luke CJ, Moyer RW, Pemberton PA, Remold-O'Donnell E, Salvesen GS, Travis J, Whisstock JC. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. *J Biol Chem*. 2001;276:33293–33296.
  33. Patston PA, Gettins PG. Significance of secondary structure predictions on the reactive center loop region of serpins: a model for the folding of serpins into a metastable state. *FEBS Lett*. 1996;383:87–92.
  34. Ness RB, Sibai BM. Shared and disparate components of the pathophysiology of fetal growth restriction and preeclampsia. *Am J Obstet Gynecol*. 2006;195:40–49.
  35. Matouskova M, Blazkova J, Pajer P, Pavlicek A, Hejnar J. CpG methylation suppresses transcriptional activity of human syncytin-1 in non-placental tissues. *Exp Cell Res*. 2006;312:1011–1020.
  36. Meller M, Vadachkoria S, Luthy DA, Williams MA. Evaluation of housekeeping genes in placental comparative expression studies. *Placenta*. 2005;26:601–607.
  37. Dupont JM, Tost J, Jammes H, Gut IG. De novo quantitative bisulfite sequencing using the pyrosequencing technology. *Anal Biochem*. 2004;333:119–127.
  38. Tost J, El Abdalaoui H, Gut IG. Serial pyrosequencing for quantitative DNA methylation analysis. *Biotechniques*. 2006;40:721–726.
  39. Klingenhoff A, Frech K, Quandt K, Werner T. Functional promoter modules can be detected by formal models independent of overall nucleotide sequence similarity. *Bioinformatics*. 1999;15:180–186.
  40. Roberts JM, Speer P. Antioxidant therapy to prevent preeclampsia. *Semin Nephrol*. 2004;24:557–564.
  41. Villar J, Abalos E, Nardin JM, Merialdi M, Carroli G. Strategies to prevent and treat preeclampsia: evidence from randomized controlled trials. *Semin Nephrol*. 2004;24:607–615.
  42. Tong YK, Lo YM. Plasma epigenetic markers for cancer detection and prenatal diagnosis. *Front Biosci*. 2006;11:2647–2656.
  43. Wang Y, Gu Y, Zhang Y, Lewis DF, Alexander JS, Granger DN. Increased chymotrypsin-like protease (chymase) expression and activity in placentas from women with preeclampsia. *Placenta*. In press.
  44. Lok CA, Boing AN, Reitsma PH, van der Post JA, van Bavel E, Boer K, Sturk A, Nieuwland R. Expression of inflammation-related genes in endothelial cells is not directly affected by microparticles from preeclamptic patients. *J Lab Clin Med*. 2006;147:310–320.
  45. Sargent IL, Borzychowski AM, Redman CW. NK cells and human pregnancy - an inflammatory view. *Trends Immunol*. 2006;27:399–404.
  46. Horvath AJ, Irving JA, Rossjohn J, Law RH, Bottomley SP, Quinsey NS, Pike RN, Coughlin PB, Whisstock JC. The murine orthologue of human antichymotrypsin: a structural paradigm for clade A3 serpins. *J Biol Chem*. 2005;280:43168–43178.
  47. Herrera-Mendez CH, Bremaud L, Coulis G, Pelissier P, Sentandreu MA, Aubry L, Delourme D, Chambon C, Maftah A, Leveziel H, Ouali A. Purification of the skeletal muscle protein Endopin 1B and characterization of the genes encoding Endopin 1A and 1B isoforms. *FEBS Lett*. 2006;580:3477–3484.
  48. Herrler A, von Rango U, Beier HM. Embryo-maternal signalling: how the embryo starts talking to its mother to accomplish implantation. *Reprod Biomed Online*. 2003;6:244–256.
  49. Booth NA. Fibrinolysis and thrombosis. *Baillieres Best Pract Res Clin Haematol*. 1999;12:423–433.
  50. Estelles A, Gilabert J, Keeton M, Eguchi Y, Aznar J, Grancha S, Espna F, Loskutoff DJ, Schleeff RR. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation. *Blood*. 1994;84:143–150.
  51. Grancha S, Estelles A, Gilabert J, Chirivella M, Espana F, Aznar J. Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation. *Thromb Haemost*. 1996;76:761–767.
  52. Braekke K, Holthe MR, Harsem NK, Fagerhol MK, Staff AC. Calprotectin, a marker of inflammation, is elevated in the maternal but not in the fetal circulation in preeclampsia. *Am J Obstet Gynecol*. 2005;193:227–233.
  53. Pidoux G, Gerbaud P, Laurendeau I, Guibourdenche J, Bertin G, Vidaud M, Evain-Brion D, Frenco JL. Large variability of trophoblast gene expression within and between human normal term placentae. *Placenta*. 2004;25:469–473.
  54. Uszynski M, Maciejewski K, Uszynski W, Kuczynski J. Placenta and myometrium—the two main sources of fibrinolytic components during pregnancy. *Gynecol Obstet Invest*. 2001;52:189–193.
  55. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo AP, Hata A, Corvol P, Lalouel JM. Haplotypes of angiotensinogen in essential hypertension. *Am J Hum Genet*. 1997;60:1448–1460.
  56. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki M, Corvol P, Lifton RP, Lalouel JM. A molecular variant of angiotensinogen associated with preeclampsia. *Nat Genet*. 1993;4:59–61.
  57. Kobashi G, Hata A, Shido K, Kato EH, Yamada H, Fujimoto S, Kishi R, Kondo K. Association of a variant of the angiotensinogen gene with pure type of hypertension in pregnancy in the Japanese: implication of a racial

- difference and significance of an age factor. *Am J Med Genet.* 1999;86:232–236.
58. Lalouel JM, Rohrwasser A, Terreros D, Morgan T, Ward K. Angiotensinogen in essential hypertension: from genetics to nephrology. *J Am Soc Nephrol.* 2001;12:606–615.
  59. Yagel S, Parhar RS, Jeffrey JJ, Lala PK. Normal non-metastatic human trophoblast cells share in vitro invasive properties of malignant cells. *J Cell Physiol.* 1988;136:455–462.
  60. Soundararajan R, Rao AJ. Trophoblast 'pseudo-tumorigenesis': significance and contributory factors. *Reprod Biol Endocrinol.* 2004;2:15.
  61. Wenger RH, Kvietikova I, Rolfs A, Camenisch G, Gassmann M. Oxygen-regulated erythropoietin gene expression is dependent on a CpG methylation-free hypoxia-inducible factor-1 DNA-binding site. *Eur J Biochem.* 1998;253:771–777.
  62. Ressler J, Stolze I, Frede S, Freitag P, Schweigerer L, Havers W, Fandrey J. Hypoxia-induced erythropoietin expression in human neuroblastoma requires a methylation free HIF-1 binding site. *J Cell Biochem.* 2004;93:153–161.
  63. Fournier T, Pavan L, Tarrade A, Schoonjans K, Auwerx J, Rochette-Egly C, Evain-Brion D. The role of PPAR-gamma/RXR-alpha heterodimers in the regulation of human trophoblast invasion. *Ann N Y Acad Sci.* 2002;973:26–30.
  64. Tarrade A, Schoonjans K, Guibourdenche J, Bidart JM, Vidaud M, Auwerx J, Rochette-Egly C, Evain-Brion D. PPAR gamma/RXR alpha heterodimers are involved in human CG beta synthesis and human trophoblast differentiation. *Endocrinology.* 2001;142:4504–4514.
  65. Chim SS, Tong YK, Chiu RW, Lau TK, Leung TN, Chan LY, Oudejans CB, Ding C, Lo YM. Detection of the placental epigenetic signature of the maspin gene in maternal plasma. *Proc Natl Acad Sci U S A.* 2005;102:14753–14758.
  66. Hwang SR, Steineckert B, Yasothornsrikul S, Sei CA, Toneff T, Rattan J, Hook VY. Molecular cloning of endopin 1, a novel serpin localized to neurosecretory vesicles of chromaffin cells. Inhibition of basic residue-cleaving proteases by endopin 1. *J Biol Chem.* 1999;274:34164–34173.
  67. Hook VY, Hwang SR. Novel secretory vesicle serpins, endopin 1 and endopin 2: endogenous protease inhibitors with distinct target protease specificities. *Biol Chem.* 2002;383:1067–1074.



**Expressional and Epigenetic Alterations of Placental Serine Protease Inhibitors:  
SERPINA3 Is a Potential Marker of Preeclampsia**

Sonia T. Chelbi, Françoise Mondon, Hélène Jammes, Christophe Buffat, Thérèse-Marie Mignot, Jorg Tost, Florence Busato, Ivo Gut, Régis Rebourcet, Paul Laissue, Vassili Tsatsaris, François Goffinet, Virginie Rigourd, Bruno Carbonne, Françoise Ferré and Daniel Vaiman

*Hypertension*. 2007;49:76-83; originally published online November 6, 2006;

doi: 10.1161/01.HYP.0000250831.52876.cb

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2006 American Heart Association, Inc. All rights reserved.

Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the  
World Wide Web at:

<http://hyper.ahajournals.org/content/49/1/76>

Data Supplement (unedited) at:

<http://hyper.ahajournals.org/content/suppl/2006/11/03/01.HYP.0000250831.52876.cb.DC1>

**Permissions:** Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

**Reprints:** Information about reprints can be found online at:

<http://www.lww.com/reprints>

**Subscriptions:** Information about subscribing to *Hypertension* is online at:

<http://hyper.ahajournals.org/subscriptions/>